Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial.
chemotherapy-related toxicities
nurse telephone monitoring intervention
patient-reported outcome measures
quality of life
randomized multicenter trial
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
04
2022
accepted:
17
08
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
4
10
2022
Statut:
epublish
Résumé
Anticancer treatment-related toxicities can impact morbidity and mortality, hamper the administration of treatment, worsen the quality of life and increase the burden on the healthcare system. Therefore, their prompt identification is crucial. NICSO (Italian Network for Supportive Care in Cancer) conducted a nationwide randomized trial to evaluate the role of a planned, weekly phone-based nurse monitoring intervention to prevent and treat chemotherapy, targeted therapy- and immunotherapy-related toxicities. Here, we report the results from the chemotherapy arm. This was a nationwide, randomized, open-label trial conducted among 29 Italian centers (NCT04726020) involving adult patients with breast, colon, or lung cancer and a life expectancy ≥6 months receiving adjuvant chemotherapy. Patients received either a weekly nurse monitoring phone call and an educational leaflet reporting practical advice about prevention and treatment of toxicities (experimental group) or the educational leaflet only (control group). The addition of a nurse monitoring intervention may help reduce time spent with severe toxicities (grade ≥3), particularly those less frequently reported in clinical practice, such as fatigue. When considering grade 1-2 AEs, times with mild/moderate diarrhea, mucositis, fatigue and pain were shorter in the experimental arm. Time spent without AEs was significantly longer in the experimental arms for all the toxicities. The requirement for special medical attention was comparable between groups. This study suggests the need for implementing a better system of toxicity assessment and management for patients treated with adjuvant chemotherapy to promote effective preventive and/or therapeutic intervention against these events.
Identifiants
pubmed: 36185306
doi: 10.3389/fonc.2022.925366
pmc: PMC9520968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
925366Informations de copyright
Copyright © 2022 Antonuzzo, Ripamonti, Roila, Sbrana, Galli, Miccinesi, Sammarco, Berruti, Coletta, Velutti, Fabi, Corsi, Mariani, Di Pede, Spinelli, Santini, Zustovich, Gunnellini, Rossi, Giordano, Di Maio, Numico and Bossi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Support Care Cancer. 2020 Aug;28(8):3897-3904
pubmed: 31848704
Support Care Cancer. 2018 Feb;26(2):557-564
pubmed: 28871358
Ann Oncol. 2015 Sep;26(9):1846-1858
pubmed: 25888610
BMJ. 2021 Jul 21;374:n1647
pubmed: 34289996
J Clin Oncol. 2009 Dec 20;27(36):6191-8
pubmed: 19917849
J Public Health Med. 2001 Sep;23(3):227-34
pubmed: 11585196
Support Care Cancer. 2009 Apr;17(4):437-44
pubmed: 18953579
Cochrane Database Syst Rev. 2020 Jun 2;6:CD007568
pubmed: 32483832
Crit Care. 2017 Apr 14;21(1):89
pubmed: 28407743
Biomed Res Int. 2016;2016:3989286
pubmed: 26981530
J Clin Oncol. 2021 Jun 20;39(18):1983-1994
pubmed: 33822650
JAMA Oncol. 2018 Jan 01;4(1):105-117
pubmed: 28570732
Ann Oncol. 2020 Jun;31(6):713-723
pubmed: 32173483
JAMA Oncol. 2017 Aug 01;3(8):1043-1050
pubmed: 28208174
Support Care Cancer. 2019 Dec;27(12):4525-4534
pubmed: 30915567
Nat Rev Clin Oncol. 2016 May;13(5):319-25
pubmed: 26787278
Am Soc Clin Oncol Educ Book. 2018 May 23;38:13-19
pubmed: 30231401
Lancet Haematol. 2020 Jun;7(6):e490-e497
pubmed: 32470440
Lancet Oncol. 2016 May;17(5):663-70
pubmed: 27083333
Eur J Oncol Nurs. 2017 Feb;26:63-82
pubmed: 28069154
Ann Transl Med. 2016 Jul;4(14):272
pubmed: 27563659
J Clin Oncol. 2021 Mar 1;39(7):734-747
pubmed: 33417506
JCO Oncol Pract. 2021 Mar;17(3):e386-e396
pubmed: 32853122
Oncotarget. 2017 Sep 18;8(50):87598-87606
pubmed: 29152104
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Pain Pract. 2021 Apr;21(4):388-393
pubmed: 33200548
Support Care Cancer. 2019 Nov;27(11):4099-4106
pubmed: 30783815
J Cancer Surviv. 2021 Feb;15(1):163-177
pubmed: 32986232
J Patient Rep Outcomes. 2020 Oct 30;4(1):88
pubmed: 33125537
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
J Med Internet Res. 2019 Mar 28;21(3):e9958
pubmed: 30920373